Phase 1 Trial of STX-478 Shows Promise for PI3K-Mutated Solid Tumors with Reduced Toxicity
/in Clinical Trial, Non-Metastatic, Phase 1/by MaxIn Vivo: CRISPR/Cas9 Gene Editing Shows Promise in Prostate Cancer Treatment
/in CRISPR, Preclinical Research/by MaxIn Vitro: Targeted Cancer Therapy with 4armPEG-DD: A Precision Approach for Prostate Cancer
/in Delivery, Preclinical Research/by MaxIn vivo: Menadione Sodium Bisulfite (vitamin K3) as a Pro-Oxidant Therapy for Prostate Cancer
/in Preclinical Research/by MaxPost-hoc of ARASENS for metastatic hormone sensitive prostate cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxDarolutamide Plus ADT and Docetaxel Extends Survival in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk in ARASENS Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxARX517 Achieves Key Safety and Efficacy Milestones in Phase 1/2 Trials for Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- A-DREAM Trial Suggests Some Men with Metastatic Prostate Cancer May Stop Therapy Safely for a Time May 22, 2026
- Phase 2 TALENT Trial: Talazoparib as Monotherapy or With Enzalutamide in HRR-deficient mCRPC May 22, 2026
- ABBV-969 in mCRPC: Dual‑Targeting ADC Shows Robust PSA and Objective Responses in Heavily Pretreated Patients May 22, 2026
- CONVERGE-01: CONV01-α Shows Activity After Lu-PSMA in mCRPC May 22, 2026